RPRX
HEALTHCARERoyalty Pharma Plc
AI Insight
What's Moving RPRX Today?
No stock-specific AI insight has been generated for RPRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$33.57$56.50
$54.28
Fundamentals
Market Cap$31.9B
P/E Ratio29.1
EPS$1.90
Dividend Yield1.67%
Dividend / Share$0.90
ROE13.8%
Profit Margin33.9%
Debt / Equity—
Trading
Volume4.2M
Avg Volume (10D)—
Shares Outstanding443.3M
RPRX News
23 articles- Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)Yahoo Finance·Jun 15, 2026
- This Royalty Pharma Insider Reduced Their Stake By 10%Yahoo Finance·Jun 12, 2026
- 3 Unpopular Stocks We’re Skeptical OfYahoo Finance·Jun 12, 2026
- Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?Yahoo Finance·Jun 10, 2026
- Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?Yahoo Finance·Jun 9, 2026
- Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·Jun 4, 2026
- Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could MeanMotley Fool·May 30, 2026
- Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth PotentialYahoo Finance·May 25, 2026
- 3 Mid-Cap Stocks We Steer Clear OfYahoo Finance·May 20, 2026
- Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market DominanceYahoo Finance·May 18, 2026
- Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst QuestionsYahoo Finance·May 16, 2026
- Anaptys Announces First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 12, 2026
- Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend SoonYahoo Finance·May 11, 2026
- Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% RallyMotley Fool·May 10, 2026
- This Fund Cashed Out of Preformed Line Products Amid a 150% Stock SurgeMotley Fool·May 8, 2026
- 10% Of This Royalty Pharma Insider's Holdings Were SoldYahoo Finance·May 8, 2026
- Royalty Pharma to present at upcoming investor conferencesYahoo Finance·May 7, 2026
- Royalty Pharma Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Royalty Pharma plc Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- RPRX vs. AMGN: Which Stock Is the Better Value Option?Yahoo Finance·May 6, 2026
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationGlobeNewswire Inc.·Apr 21, 2026
- Royalty Pharma Declares Second Quarter 2026 DividendBenzinga·Apr 17, 2026
- Zymeworks Appoints Kristin Stafford as Chief Financial OfficerGlobeNewswire Inc.·Apr 1, 2026
All 23 articles loaded
Price Data
Open$55.16
Previous Close$55.35
Day High$55.57
Day Low$54.20
52 Week High$56.50
52 Week Low$33.57
52-Week Range
$33.57$56.50
$54.28
Fundamentals
Market Cap$31.9B
P/E Ratio29.1
EPS$1.90
Dividend Yield1.67%
Dividend / Share$0.90
ROE13.8%
Profit Margin33.9%
Debt / Equity—
Trading
Volume4.2M
Avg Volume (10D)—
Shares Outstanding443.3M
About Royalty Pharma Plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—